logo-loader

Tissue Regenix focused on securing further strategic partnerships

Published: 08:34 27 Mar 2018 EDT

"We are now in the position of really trying to kick on in 2018'', Couldwell says

Steve Couldwell, chief executive of Tissue Regenix PLC (LON:TRX), tells Proactive that 2017 has been a year of transformation, boosted by the acquisition of CellRight.

“That was the transformation the company really needed, and the integration of that business has gone extremely well ... we are now in the position of really trying to kick on in 2018'', Couldwell says.

Since the end of the reporting period, the group's announced strategic partnerships with ARMS Medical for DermaPure and with Arthrex for the distribution of CellRight’s ‘BioRinse’ portfolio.

Tissue Regenix Group "has the opportunity to become a global commercial...

Tissue Regenix Group PLC (AIM:TRX, OTC:TSSNF) chief executive Danny Lee and chief financial officer David Cocke speak to Proactive's Thomas Warner after releasing a trading update for 2022. They reveal their highlights from the year before looking ahead to what investors can expect from the...

on 02/02/2023